Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christine Do

Showing results (91-100 of 117) with videos related to

Pageof 12
Sort By:
Hormones & Cancer|October 27, 2017
Time Until Partial Response in Metastatic Adrenocortical Carcinoma Long-Term SurvivorsDelphine Vezzosi, Christine Do Cao, Ségolène Hescot, et al.
United European Gastroenterology Journal|October 31, 2019
Endoscopic management of 345 small rectal neuroendocrine tumours: A national study from the French group of endocrine tumours (GTE)Caroline Fine, Guillaume Roquin, Eric Terrebonne, et al.
Thyroid : Official Journal of the American Thyroid Association|March 30, 2017
Molecular Pathology of Anaplastic Thyroid Carcinomas: A Retrospective Study of 144 CasesBenjamin Bonhomme, Yann Godbert, Gaelle Perot, et al.
European Journal of Cancer (Oxford, England : 1990)|March 17, 2017
A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU studyAlain Ravaud, Christelle de la Fouchardière, Philippe Caron, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 25, 2024
Oxaliplatin-Based Versus Alkylating Agent in Neuroendocrine Tumors According to the O<sup>6</sup>-Methylguanine-DNA Methyltransferase Status: A Randomized Phase II Study (MGMT-NET)Thomas Walter, Thierry Lecomte, Julien Hadoux, et al.
Thyroid : Official Journal of the American Thyroid Association|August 15, 2018
Effect of Buparlisib, a Pan-Class I PI3K Inhibitor, in Refractory Follicular and Poorly Differentiated Thyroid CancerFrancoise Borson-Chazot, Emmanuelle Dantony, Frederic Illouz, et al.
The Journal of Clinical Endocrinology and Metabolism|July 26, 2013
Is thyroid cancer recurrence risk increased after transplantation?Hélène Tisset, Nassim Kamar, Isabelle Faugeron, et al.
The Lancet. Oncology|October 28, 2017
Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trialPiero Ferolla, Maria Pia Brizzi, Tim Meyer, et al.
The Journal of Clinical Endocrinology and Metabolism|December 5, 2022
Efficacy and Safety of Osilodrostat in Paraneoplastic Cushing Syndrome: A Real-World Multicenter Study in FranceAlexandre Dormoy, Magalie Haissaguerre, Géraldine Vitellius, et al.
Annales D'Endocrinologie|July 31, 2018
Endocrine side-effects of new anticancer therapies: Overall monitoring and conclusionsFrédéric Castinetti, Frédéric Albarel, Françoise Archambeaud, et al.
Pageof 12

Showing results (91-100 of 117) with videos related to

Sort By:
Pageof 12
Hormones & Cancer|October 27, 2017
Time Until Partial Response in Metastatic Adrenocortical Carcinoma Long-Term SurvivorsDelphine Vezzosi, Christine Do Cao, Ségolène Hescot, et al.
United European Gastroenterology Journal|October 31, 2019
Endoscopic management of 345 small rectal neuroendocrine tumours: A national study from the French group of endocrine tumours (GTE)Caroline Fine, Guillaume Roquin, Eric Terrebonne, et al.
Thyroid : Official Journal of the American Thyroid Association|March 30, 2017
Molecular Pathology of Anaplastic Thyroid Carcinomas: A Retrospective Study of 144 CasesBenjamin Bonhomme, Yann Godbert, Gaelle Perot, et al.
European Journal of Cancer (Oxford, England : 1990)|March 17, 2017
A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU studyAlain Ravaud, Christelle de la Fouchardière, Philippe Caron, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 25, 2024
Oxaliplatin-Based Versus Alkylating Agent in Neuroendocrine Tumors According to the O<sup>6</sup>-Methylguanine-DNA Methyltransferase Status: A Randomized Phase II Study (MGMT-NET)Thomas Walter, Thierry Lecomte, Julien Hadoux, et al.
Thyroid : Official Journal of the American Thyroid Association|August 15, 2018
Effect of Buparlisib, a Pan-Class I PI3K Inhibitor, in Refractory Follicular and Poorly Differentiated Thyroid CancerFrancoise Borson-Chazot, Emmanuelle Dantony, Frederic Illouz, et al.
The Journal of Clinical Endocrinology and Metabolism|July 26, 2013
Is thyroid cancer recurrence risk increased after transplantation?Hélène Tisset, Nassim Kamar, Isabelle Faugeron, et al.
The Lancet. Oncology|October 28, 2017
Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trialPiero Ferolla, Maria Pia Brizzi, Tim Meyer, et al.
The Journal of Clinical Endocrinology and Metabolism|December 5, 2022
Efficacy and Safety of Osilodrostat in Paraneoplastic Cushing Syndrome: A Real-World Multicenter Study in FranceAlexandre Dormoy, Magalie Haissaguerre, Géraldine Vitellius, et al.
Annales D'Endocrinologie|July 31, 2018
Endocrine side-effects of new anticancer therapies: Overall monitoring and conclusionsFrédéric Castinetti, Frédéric Albarel, Françoise Archambeaud, et al.
Pageof 12